Bal Pharma Limited

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

04.04.2019

BSE Limited
Mumbai.

Dear Sir,

Sub: Intimation as per Regulation 30 of SEBI(LODR) Regulations,2015.

With reference to the above, we are submitting the attached media release to the exchanges before circulating the same to the media regarding receipt of EU GMP approval for its formulations manufacturing plant at Rudrapur, Uttarakhand.

Please take the same on record.

Thanking You.

For Bal Pharma Limited

Authorised Signatory

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58
Email : info@balpharma.com Website : www.balpharma.com
CIN # L85110KA1987PLC008368
REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820

Bal Pharma Limited

Media Release

BAL PHARMA LTD RECEIVES EU GMP ACCREDITATION:

Bangalore,04/04/2019: The formulations manufacturing unit of the Company located at Rudrapur, Uttarakhand has received certification for GMP compliance for manufacturing of formulations, as per European Union regulations. This EUGMP approval allows the plant to manufacture finished dosage formulations for supplying to regulated markets including Europe, US, Japan and Australia among others.

"This EUGMP accreditation will help Company further consolidate its formulations business in regulated markets. This is a firm step in our new business plan of systematic value addition." commented Mr. Shailesh Siroya, Managing Director of the Company.

About Bal Pharma Ltd

Bal Pharma is a fully integrated pharmaceutical Company focused on manufacturing of prescription drugs, generic, OTC products and bulk actives. Over the past several years, the Company supplies its niche formulations and API's to regulated and semi regulated markets across the world thereby creating its unique position in the pharmaceutical industry. The Company caters to about 20% of the global demand for diabetic drugs through its flagship diabetes molecule, Gliclazide. The R&D team has supported production and formulation of NCEs. The Company has its marketing and sales presence in more than 40 countries across the world. The Company has acquired API manufacturing facility at Udaipur and entered into a JV with an Australian pharma major i.e Akaal Pharma Ltd for the development of patented veterinary products with an aim to enhance its sales activities both in Indian and International markets , for its envisaged aggressive growth plans.

For Further queries , please contact
Y.Venu Madhava Reddy
Email : info@balpharma.com
Phone : 080 41379500.